Press Releases

Sign up for Email Alerts Press Release RSS

03/09/2020
Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma
Term:Corporate/Financial News
Language:English
03/03/2020
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics For Oncology
Term:
Language:English
03/02/2020
CORRECTING and REPLACING Bristol‑Myers Squibb Announces Dividend
Term:Corporate/Financial News
Language:English
02/21/2020
Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer
Term:Corporate/Financial News
Language:English
02/19/2020
Bristol-Myers Squibb to Hold Investor Day on April 2
Term:Corporate/Financial News
Language:English
02/15/2020
Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma
Term:Corporate/Financial News
Language:English
02/15/2020
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Term:Corporate/Financial News
Language:English
02/14/2020
Multinational Inflammatory Bowel Disease Survey Uncovers Striking Differences in Patients’ and Physicians’ Treatment Goals and Disease Management Expectations
Term:Corporate/Financial News
Language:English
02/13/2020
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma
Term:
Language:English
02/06/2020
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm

Cookie Settings